Thermo Fisher (TMO) Stock Climbs After Blowout Quarter Eases Sector Concerns

TLDR

• TMO jumped more than 5% in premarket trading after beating Q2 2026 earnings and revenue estimates
• Adjusted EPS came in at $6.03, topping the $5.72 consensus; revenue hit $11.99B vs. $10.85B a year ago
• Organic revenue grew 5% year over year, with Laboratory Products and Biopharma Services leading at $6.69B
• Thermo Fisher raised its full-year 2026 adjusted EPS guidance to $24.93–$25.33 and revenue outlook to $47.4B–$48.1B
• The Q2 beat helps ease concerns sparked by peer Danaher’s weak Q3 outlook earlier this week

---

Thermo Fisher Scientific (TMO) rose more than 5% in premarket trading on Thursday after reporting second-quarter results that topped Wall Street estimates on both the top and bottom lines.

Thermo Fisher Scientific Inc., TMO

The stock had been under pressure earlier in the week following a disappointing outlook from peer Danaher (DHR), making Thursday’s beat a welcome turnaround for investors.

Adjusted EPS came in at $6.03, well ahead of the $5.72 consensus estimate. That represents roughly 13% growth year over year.

THERMO FISHER SCIENTIFIC $TMO Q2’26 EARNINGS HIGHLIGHTS

🔹 Revenue: $11.99B (Est. $11.7B) 🟢; +10% YoY
🔹 Adj. EPS: $6.03 (Est. $5.71) 🟢; +13% YoY
🔹 Organic Revenue Growth: 5%

Other Q2 Metrics:
🔹 Organic Revenue Growth: 5%
🔹 GAAP Operating Margin: 17.4%; +50 bps YoY
🔹… pic.twitter.com/qyMZuYbeFt

— Wall St Engine (@wallstengine) July 23, 2026

Revenue for the quarter ended June 27, 2026 reached $11.99 billion, up 10% from $10.85 billion in the same period last year. Analysts had expected $11.71 billion.

Organic revenue grew 5% during the quarter, reflecting demand across multiple business units.

The Laboratory Products and Biopharma Services segment was the biggest driver, bringing in $6.69 billion — about 55.8% of total revenue. That unit grew roughly 12% year over year.

Life Sciences Solutions added $2.8 billion, up about 13%, while Analytical Instruments contributed $1.8 billion, up roughly 7%.

Guidance Raised for Full Year 2026

Management used the earnings call to lift its full-year outlook. Thermo Fisher now guides for adjusted EPS of $24.93 to $25.33, up from the prior range of $24.64 to $25.12. The consensus was sitting at $24.85.

Full-year revenue guidance was also nudged higher, to $47.4 billion to $48.1 billion from $47.3 billion to $48.1 billion. That midpoint now exceeds the $47.76 billion analysts had projected.

CEO Marc Casper said the company is “well positioned to deliver a great 2026” at the halfway point of the year.

Adjusted operating margin expanded to 22.8% from 21.9% in the prior-year period. GAAP diluted EPS rose 9% to $4.68.

Capital Returns and New Products

During the quarter, Thermo Fisher repurchased $1.0 billion of its own stock and announced plans to divest its microbiology business as part of a portfolio cleanup.

The company also launched its next-generation Orbitrap platforms with AI-driven analytics and opened a new Bioprocess Design Center in Plainville, Massachusetts.

Casper credited the company’s PPI Business System and what he called “excellent execution” from the team for driving the outperformance.

The Q2 results are seen as a counterpoint to the sector-wide worry that followed Danaher’s softer-than-expected Q3 2026 outlook on Tuesday.